For example, BTK has been shown to modulate PD-1 expression in DLBCL cells in vitro, which raises the possibility that combinations of BTK inhibitors with immune checkpoint inhibitors may increase efficacy (70). Here, PDCD1 is linked to diffuse large B-cell lymphoma.